Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 46

Results For "ASH"

2930 News Found

PAI Pharma acquires Nivagen to boost US injectable drug production
News | January 11, 2026

PAI Pharma acquires Nivagen to boost US injectable drug production

The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing


Shilpa Medicare aims for US approval of chemo nausea drug
News | January 09, 2026

Shilpa Medicare aims for US approval of chemo nausea drug

Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections


WHO unveils updated HIV guidelines to boost treatment & save lives
News | January 09, 2026

WHO unveils updated HIV guidelines to boost treatment & save lives

The guidelines also support reusing tenofovir and abacavir in later regimens for improved outcomes, cost savings, and programmatic efficiency


Oculis’ Privosegtor wins FDA breakthrough therapy status for Optic Neuritis
News | January 09, 2026

Oculis’ Privosegtor wins FDA breakthrough therapy status for Optic Neuritis

The FDA designation follows visual-function results from the Phase 2 ACUITY trial


BeOne Medicines wins first-in-world nod for Sonrotoclax in China
Drug Approval | January 09, 2026

BeOne Medicines wins first-in-world nod for Sonrotoclax in China

The approval is backed by data showing deep, durable responses and manageable tolerability


Leeford Healthcare bets Rs. 200 crore on orthopedic & mobility aids
Healthcare | January 09, 2026

Leeford Healthcare bets Rs. 200 crore on orthopedic & mobility aids

Tiger Shroff fronts ‘Fit Raho, Hit Raho’ campaign


Lilly to buy Ventyx Biosciences for $1.2 billion
News | January 08, 2026

Lilly to buy Ventyx Biosciences for $1.2 billion

Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation


Amgen snaps up UK biotech Dark Blue Therapeutics in up to $840m oncology deal
Biotech | January 08, 2026

Amgen snaps up UK biotech Dark Blue Therapeutics in up to $840m oncology deal

The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation